[ad_1] This is good news for the moist AMD drug from Allergan and Molecular Partners. The duo announced Thursday that abicipar had achieved its goals in two phase III trials, proving the …
Read More »In two PhIII wins for Allergan / Molecular Partners, wet AMD drug shows non-inferiority to Lucentis – Endpoints News
